Company: PSTV
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001140361-25-008857
Chunk: 12

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 12
---
 rely only on the information provided in this Proxy Statement. We have not authorized anyone to provide you with different or additional information. You should not assume that the information in this Proxy Statement is accurate as of any date other than the date of this Proxy Statement or, where information relates to another date set forth in this Proxy Statement, then as of that date.

Important notice regarding the availability of proxy materials for our Special Meeting of stockholders to be held on [] , 2025:

On or about [ ], 2025, proxy materials for the Special Meeting, including the attached proxy statement, are being furnished to stockholders entitled to vote at the Special Meeting. The proxy statement and our periodic reports filed with the U.S. Securities and Exchange are available on our Investor Relations website at https://ir.plustherapeutics.com/reports-filings/quarterly-results. You can also view the Special Meeting materials at [ Link ] by using the control number provided on your proxy card or the Notice.

<div align='center'>6</div>

TABLE OF CONTENTS

PROPOSAL 1: THE REVERSE STOCK SPLIT PROPOSAL Our Board has unanimously approved and declared advisable and is recommending that our stockholders approve and adopt a proposed amendment to our Certificate of Incorporation to combine the outstanding shares of our Common Stock into a lesser number of outstanding shares, in substantially the form attached hereto as Annex A, to effect a reverse stock split of all of our outstanding shares of Common Stock at a specific ratio within a range of one-for-twenty five (1-for-25) to a maximum of a one-for-two hundred fifty (1-for-250), (the “Reverse Stock Split”), with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined by our Board, in its sole discretion and without further action by the Company’s stockholders; provided, our Board will not select a reverse split ratio that will result in us having fewer than 500,000 publicly held shares under Nasdaq continued listing standards. The following table contains approximate information relating to our Common Stock immediately following the Reverse Stock Split under certain possible exchange ratios, based on share information as of March 4, 2025 (all share numbers are rounded down to the nearest whole share):

|                                                                       |     |      Prior to 
       Reverse 
   Stock Split |     | Giving Effect to Reverse Stock Split at Ratio of: |     |             |     |